The recombintant humanised anti VEGF monoclonal antibody Bevacizumab has been extensively investigated in CRT schedules in rectal cancer. In a Phase I/II trial in rectal cancer patients receiving bevacizumab and CRT (158), provided direct evidence of the antivascular effect of anti-VEGF treatment by functional, cellular, and molecular investigations. Inhibitors,research,lifescience,medical Briefly, bevacizumab decreases the tumor vascular density, tumor perfusion, tumor interstitial fluid pressure, and

the number of viable circulating endothelial and progenitor cells, which results into a significant increase in apoptosis of cancer cells (158). Several phase I/II trials reported on the feasibility of adding bevacizumab to 5-FU based CRT in the neo-adjuvant setting of locally advanced rectal cancer, and provided encouraging pCR rates with moderate toxicity (66,159). The reported incidence of postoperative wound complications Inhibitors,research,lifescience,medical in up to 36% of the patients is however concerning and consistent with other reports utilizing bevacizumab with CRT before a major surgical Inhibitors,research,lifescience,medical procedure (72). The more recent AVACROSS study selected 47 patients according to MRI criteria, and used 4 cycles of induction chemotherapy using capecitabine, oxaliplatin and bevacizumab, followed by chemoradiation with concurrent capecitabine and bevacizumab (70).Results are impressive with

98% having an R0 resection and 34% achieved a pCR, with an additional 17 patients (36%) achieving Dworak tumor regression grade 3. Besides pCR, 23% were downstaged Inhibitors,research,lifescience,medical to ypT1/T2N0. There was one sudden death during the induction, and surgical morbidity appears prominent, since 26/45 patients (58%) experienced at least one postoperative complication and 11/45 (24%) required surgical re-intervention (even though

the median time from the last dose of bevacizumab to surgery was 2 months). A phase 2 trial Inhibitors,research,lifescience,medical evaluate preoperative capecitabine, oxaliplatin, and bevacizumab with radiation therapy followed by surgery and postoperative 5-FU, SCR7 mouse leucovorin, oxaliplatin (FOLFOX) and bevacizumab for locally advanced rectal cancer in 57 patients (77). 17% achieved a pathologic complete PDGFR inhibitor response, but 47% of patients who underwent surgery experienced a surgical complication. A Canadian study achieved a pCR of 18%, but 4 patients (11%) required re-operation due to complications (75). A further study evaluating bevacizumab/chemoradiation in the preoperative and adjuvant settings in 66 patients with stage II/III rectal cancer (76) achieved a pCR rate of 29%, but again showed frequent grade 3/4 toxicity and surgical morbidity. A systematic review reported 15 trials over the past decade which incorporated bevacizumab into a neo-adjuvant CRT schedule (160). The pooled pCR rate of 21% is not better than in trials reported with 5-FU based CRT alone.